Pfizer cash flow

Latest FY26
Cash from operations
₹968cr+46.7% on FY25
Capital spending
₹25.2cr−10.4% on FY25
Free cash flow
₹942cr+49.2% on FY25
Cash from financing
−₹798cr−₹205 cr in FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Adjustments to reconcile profit — non-cash items
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
—57.760.862.3—
—9.58.415.4—
—−166−157−132—
Changes in working capital
—−25.2−42.2−16.0—
—9.1−6.8−36.5—
—63.3−15.3−50.2—
Cash from operating activities
9939761,016746824
—953816411—
—14.5156154—
—968660257—
Cash from investing activities
—25.228.218.9—
—1.20.20.0—
—177139129—
—−562−71.353.7—
Cash from financing activities
—34.037.341.1—
—−798−205−235—
——383——
—103495112—
Reference items
942904740635809
36.6%35.9%32.5%29.0%33.4%
942942632238—
—1.34×0.86×0.47×—
—14.5156154—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

PFIZER₹3,734.40

Pfizer Ltd.

· Pharma & Health
₹ CrorePeersGLAXOABBOTINDIAPOLYMEDONESOURCERAINBOWKIMSJUBLPHARMAVIJAYA
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation—62.360.857.7—
+ Finance Costs—15.48.49.5—
+ Interest Income—-132.5-157.3-165.7—
Changes in Working Capital
+ Inventories—-16.0-42.2-25.2—
+ Trade Receivables — Current—-36.5-6.89.1—
+ Trade Payables — Current—-50.2-15.363.3—
Cash from Operating Activities
Profit Before Tax (per I/S)824.0746.11,016.1975.7992.8
Cash from Operations (pre-tax)—410.7816.0953.0—
+ Income Taxes Paid—153.8156.214.5—
Cash from Operating Activities—256.8659.8967.6—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)—18.928.225.2—
+ Disp of Fixed Assets—0.00.21.2—
+ Interest Received — Investing—128.8139.4177.0—
Cash from Investing Activities—53.7-71.3-561.7—
Cash from Financing Activities
+ Payment of Lease Liabilities—41.137.334.0—
Cash from Financing Activities—-235.1-205.3-798.3—
Net Changes in Cash——383.1——
Closing Cash—112.0495.1102.7—
Reference Items
EBITDA808.9635.3740.2904.1941.6
EBITDA Margin %33.3628.9732.4535.8836.64
Free Cash Flow (CFO − Capex)—237.9631.6942.3942.3
Cash Flow to Net Income—0.470.861.34—
Cash Paid for Taxes—153.8156.214.5—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.